KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $674.1 million.

  • Emergent BioSolutions' Non-Current Assets fell 1743.02% to $674.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year decrease of 2685.84%. This contributed to the annual value of $791.0 million for FY2024, which is 3083.85% down from last year.
  • Emergent BioSolutions' Non-Current Assets amounted to $674.1 million in Q3 2025, which was down 1743.02% from $697.6 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Non-Current Assets ranged from a high of $2.0 billion in Q4 2022 and a low of $674.1 million during Q3 2025
  • Moreover, its 5-year median value for Non-Current Assets was $1.4 billion (2023), whereas its average is $1.3 billion.
  • As far as peak fluctuations go, Emergent BioSolutions' Non-Current Assets skyrocketed by 1588.46% in 2022, and later plummeted by 4152.56% in 2023.
  • Emergent BioSolutions' Non-Current Assets (Quarter) stood at $1.7 billion in 2021, then increased by 15.88% to $2.0 billion in 2022, then tumbled by 41.53% to $1.1 billion in 2023, then plummeted by 30.84% to $791.0 million in 2024, then dropped by 14.78% to $674.1 million in 2025.
  • Its last three reported values are $674.1 million in Q3 2025, $697.6 million for Q2 2025, and $719.3 million during Q1 2025.